Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015397316> ?p ?o ?g. }
- W2015397316 endingPage "325" @default.
- W2015397316 startingPage "317" @default.
- W2015397316 abstract "What is already known about this subject? The naturally occurring interlukin-1 receptor antagonist (IL-1RA) markedly protects rodents against ischaemic, excitotoxic and traumatic brain injury, suggesting it may be of therapeutic value. When administered intravenously to patients soon after stroke, IL-1RA is safe and reduces the peripheral inflammatory response. However, IL-1RA is a large protein (17 kDa), which may limit brain penetration, thereby limiting its potential utility in brain injury. What this study adds. The purpose of these experiments was to determine the pharmacokinetics of IL-1RA in cerebrospinal fluid (CSF) of patients, to allow modelling that would aid development of therapeutic regimens. Peripherally administered IL-1RA crosses slowly into and out of the CSF of patients with subarachnoid haemorrhage and, at steady state, CSF IL-1RA concentration (range 115-886 ng ml(-1)) was similar to that found to be neuroprotective in rats (range 91-232 ng ml(-1)), although there was considerable variability among patients. However, there is a large concentration gradient of IL-1RA between plasma and CSF. These CSF:plasma data are consistent with very low permeation of IL-1RA into the CSF and elimination kinetics from it controlled by the volumetric turnover of CSF.The naturally occurring interlukin-1 receptor antagonist (IL-1RA) markedly protects rodents against ischaemic, excitotoxic and traumatic brain injury, suggesting it may be of therapeutic value. The aim was to determine the pharmacokinetics of IL-1RA in cerebrospinal fluid (CSF) of patients, to allow modelling that would aid development of therapeutic regimens.When administered intravenously to patients soon after stroke, IL-1RA is safe and reduces the peripheral inflammatory response. However, IL-1RA is a large protein (17 kDa), which may limit brain penetration, thereby limiting its potential utility in brain injury. In seven patients with subarchnoid haemorrhage (SAH), IL-1RA was administered by intravenous bolus, then infusion for 24 h, and both blood and CSF, via external ventricular drains, were sampled during and after stopping the infusion.Plasma steady-state concentrations were rapidly attained and maintained throughout the infusion, whereas CSF concentrations rose slowly towards a plateau during the 24-h infusion, reaching at best only 4% of that in plasma. Plasma kinetic parameters were within the literature range. Modelling of the combined data yielded rate constants entering and leaving the CSF of 0.0019 h(-1)[relative standard error (RSE) = 19%] and 0.1 h(-1) (RSE = 19%), respectively.Peripherally administered IL-1RA crosses slowly into and out of the CSF of patients with SAH. However, there is a large concentration gradient of IL-1RA between plasma and CSF. These CSF:plasma data are consistent with very low permeation of IL-1RA into the CSF and elimination kinetics from it controlled by the volumetric turnover of CSF." @default.
- W2015397316 created "2016-06-24" @default.
- W2015397316 creator A5001134449 @default.
- W2015397316 creator A5007184940 @default.
- W2015397316 creator A5016858297 @default.
- W2015397316 creator A5019779814 @default.
- W2015397316 creator A5020397401 @default.
- W2015397316 creator A5074734032 @default.
- W2015397316 creator A5083311472 @default.
- W2015397316 creator A5089684462 @default.
- W2015397316 date "2008-03-01" @default.
- W2015397316 modified "2023-09-26" @default.
- W2015397316 title "Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage" @default.
- W2015397316 cites W1497410983 @default.
- W2015397316 cites W1603121691 @default.
- W2015397316 cites W1966697017 @default.
- W2015397316 cites W1969661146 @default.
- W2015397316 cites W1978525572 @default.
- W2015397316 cites W1981724301 @default.
- W2015397316 cites W2002427402 @default.
- W2015397316 cites W2007511428 @default.
- W2015397316 cites W2023396428 @default.
- W2015397316 cites W2024187026 @default.
- W2015397316 cites W2028290269 @default.
- W2015397316 cites W2029714837 @default.
- W2015397316 cites W2044649855 @default.
- W2015397316 cites W2056765412 @default.
- W2015397316 cites W2060752639 @default.
- W2015397316 cites W2074229539 @default.
- W2015397316 cites W2082067229 @default.
- W2015397316 cites W2085060797 @default.
- W2015397316 cites W2088318869 @default.
- W2015397316 cites W2098752487 @default.
- W2015397316 cites W2109654657 @default.
- W2015397316 cites W2113191624 @default.
- W2015397316 cites W2144918294 @default.
- W2015397316 cites W2330112487 @default.
- W2015397316 cites W4237524633 @default.
- W2015397316 cites W604382646 @default.
- W2015397316 doi "https://doi.org/10.1111/j.1365-2125.2007.03026.x" @default.
- W2015397316 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2291249" @default.
- W2015397316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17875190" @default.
- W2015397316 hasPublicationYear "2008" @default.
- W2015397316 type Work @default.
- W2015397316 sameAs 2015397316 @default.
- W2015397316 citedByCount "51" @default.
- W2015397316 countsByYear W20153973162012 @default.
- W2015397316 countsByYear W20153973162013 @default.
- W2015397316 countsByYear W20153973162014 @default.
- W2015397316 countsByYear W20153973162015 @default.
- W2015397316 countsByYear W20153973162016 @default.
- W2015397316 countsByYear W20153973162017 @default.
- W2015397316 countsByYear W20153973162018 @default.
- W2015397316 countsByYear W20153973162019 @default.
- W2015397316 countsByYear W20153973162020 @default.
- W2015397316 countsByYear W20153973162021 @default.
- W2015397316 countsByYear W20153973162022 @default.
- W2015397316 countsByYear W20153973162023 @default.
- W2015397316 crossrefType "journal-article" @default.
- W2015397316 hasAuthorship W2015397316A5001134449 @default.
- W2015397316 hasAuthorship W2015397316A5007184940 @default.
- W2015397316 hasAuthorship W2015397316A5016858297 @default.
- W2015397316 hasAuthorship W2015397316A5019779814 @default.
- W2015397316 hasAuthorship W2015397316A5020397401 @default.
- W2015397316 hasAuthorship W2015397316A5074734032 @default.
- W2015397316 hasAuthorship W2015397316A5083311472 @default.
- W2015397316 hasAuthorship W2015397316A5089684462 @default.
- W2015397316 hasBestOaLocation W20153973161 @default.
- W2015397316 hasConcept C112705442 @default.
- W2015397316 hasConcept C118552586 @default.
- W2015397316 hasConcept C126322002 @default.
- W2015397316 hasConcept C149892131 @default.
- W2015397316 hasConcept C170493617 @default.
- W2015397316 hasConcept C25498285 @default.
- W2015397316 hasConcept C2776885963 @default.
- W2015397316 hasConcept C2778122271 @default.
- W2015397316 hasConcept C2779651940 @default.
- W2015397316 hasConcept C2781017439 @default.
- W2015397316 hasConcept C42219234 @default.
- W2015397316 hasConcept C71924100 @default.
- W2015397316 hasConcept C98274493 @default.
- W2015397316 hasConceptScore W2015397316C112705442 @default.
- W2015397316 hasConceptScore W2015397316C118552586 @default.
- W2015397316 hasConceptScore W2015397316C126322002 @default.
- W2015397316 hasConceptScore W2015397316C149892131 @default.
- W2015397316 hasConceptScore W2015397316C170493617 @default.
- W2015397316 hasConceptScore W2015397316C25498285 @default.
- W2015397316 hasConceptScore W2015397316C2776885963 @default.
- W2015397316 hasConceptScore W2015397316C2778122271 @default.
- W2015397316 hasConceptScore W2015397316C2779651940 @default.
- W2015397316 hasConceptScore W2015397316C2781017439 @default.
- W2015397316 hasConceptScore W2015397316C42219234 @default.
- W2015397316 hasConceptScore W2015397316C71924100 @default.
- W2015397316 hasConceptScore W2015397316C98274493 @default.
- W2015397316 hasIssue "3" @default.
- W2015397316 hasLocation W20153973161 @default.
- W2015397316 hasLocation W20153973162 @default.
- W2015397316 hasLocation W20153973163 @default.